This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
New York-based Bristol-Myers Squibb is a one of the leading global specialty bio-pharmaceutical companies focused on the development of treatments targeting serious diseases. Backed by its blockbuster immune-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, consisting of other drugs like Revlimid, Sprycel, Yervoy and Empliciti. Beyond oncology, the company has important immunology and cardiovascular drugs like Orencia and Eliquis, which diversify its portfolio. Notably, in the cardiovascular space, Eliquis is now the global leading oral anti-coagulant drug. The company continues to experience growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program..
AMAG's Label Expansion of Lead Products Raises Share Price
by Zacks Equity Research
AMAG's (AMAG) label expansion efforts for Feraheme and Makena are encouraging.
Glaxo Inks Marketing Deal for Anaemia Candidate in Japan
by Zacks Equity Research
GlaxoSmithKline (GSK) signs a collaboration contract with Japan's Kyowa Hakko Kirin for future commercialization of daprodustat in Japan.
Bayer Hurts from Generic Competition & Pipeline Setbacks
by Zacks Equity Research
Bayer (BAYRY) faces pipeline setbacks. Weak global economy outlook and generic competition are headwinds.
BMY vs. AZN: Which Stock Is the Better Value Option?
by Zacks Equity Research
BMY vs. AZN: Which Stock Is the Better Value Option?
Pfizer's FDA Nod for Cancer Drug is Four in a Row in 90 Days
by Zacks Equity Research
Pfizer (PFE) wins an FDA nod for Daurismo in combination with low-dose cytarabine regarding newly-diagnosed AML in adults. This is the fourth cancer drug approval on the trot in less than 90 days.
Mylan Recalls Valsartan Lots, Gets FDA Warning for Facility
by Zacks Equity Research
Mylan (MYL) recalls batches of blood pressure medicine in the United States. The company receives warning letter from the FDA for the manufacturing facility in Morgantown, WV.
Shire-Takeda Deal Gets Phase I Conditional European Approval
by Zacks Equity Research
Takeda's bid to acquire Shire (SHPG) receives conditional approval from the European Commission.
Is Bristol-Myers (BMY) a Great Stock for Value Investors?
by Zacks Equity Research
Let's see if Bristol-Myers Squibb Company (BMY) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.
Clovis' (CLVS) Rubraca Gets Another US Patent, Shares Up
by Zacks Equity Research
Clovis Oncology's (CLVS) shares rise more than 5% following the issuance of a new patent for Rubraca in the United States for claims related to methods of treating cancer with its high dosage strength.
Bristol-Myers Squibb (BMY) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Bristol-Myers Squibb (BMY) closed at $53.52, marking a +0.07% move from the previous day.
Pfizer's Bavencio Phase III Study for Ovarian Cancer Fails
by Zacks Equity Research
Pfizer's (PFE) late-stage advanced ovarian study on Bavencio (avelumab) fails to meet the primary endpoints.
AstraZeneca's Imfinzi Fails in Lung Cancer Study, Stock Down
by Zacks Equity Research
AstraZeneca (AZN) announced that Imfinzi as a monotherapy or in combination with tremelimumab failed to improve overall survival in first-line NSCLC. The combination had also failed to improve progression free survival last year.
Bristol-Myers' Opdivo Receives Positive CHMP Opinion for RCC
by Zacks Equity Research
Bristol-Myers' (BMY) immuno-oncology drug Opdivo combined with low-dose Yervoy gets positive opinion from CHMP for the treatment of intermediate- and poor-risk advanced RCC.
uniQure Up on Positive Data From Mid-Stage Hemophilia Study
by Zacks Equity Research
uniQure's (QURE) gene therapy candidate, AMT-061, demonstrates significant improvement in hemophilia B patients in a mid-stage study. Investors' sentiment improves.
Pharma Stock Roundup: FDA Updates on MRK, AZN's Cancer Drugs, Bayer's Q3 Earnings
by Zacks Equity Research
FDA provides updates on Merck (MRK), AstraZeneca (AZN) and Roche (RHHBY) for their cancer drugs. Bayer (BAYRY) reports strong third-quarter results.
Seattle Genetics' Adcetris Gets Breakthrough Therapy Status
by Zacks Equity Research
Seattle Genetics' (SGEN) Adcetris gets Breakthrough Therapy designation by the FDA for the frontline treatment of certain lymphoma subtypes.
Mallinckrodt Gets FDA Committee Vote for Abuse-Deterrent Drug
by Zacks Equity Research
The FDA's Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety and Risk Management Advisory Committee vote for Mallinckrodt (MNK) abuse-deterrent drug.
Exelixis, Ipsen Get EU Nod for Label Expansion of Cabometyx
by Zacks Equity Research
Exelixis (EXEL) and partner Ipsen receive EU approval for the label expansion of Cabometyx (cabozantinib) tablets as a monotherapy for HCC in adults.
Bristol-Myers Squibb (BMY) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Bristol-Myers Squibb (BMY) closed the most recent trading day at $52.61, moving +0.04% from the previous trading session.
Merck Starts Rolling BLA Submission for Ebola Vaccine V920
by Zacks Equity Research
Merck (MRK) begins the rolling submission of a BLA for its investigational Ebola vaccine candidate V920 to the FDA.
Shire's Filing Accepted by FDA for Gattex's Label Expansion
by Zacks Equity Research
The FDA accepts Shire's (SHPG) sNDA and is expected to take action in March 2019.
Bayer (BAYRY) Beats on Q3 Earnings, Revenue Estimates
by Zacks Equity Research
Bayer (BAYRY) surpasses earnings and sales estimates in the third quarter of 2018 and reiterates outlook for 2018.
Cronos (CRON) to Report Q3 Earnings: What's in the Offing?
by Zacks Equity Research
Cronos' (CRON) third-quarter results are likely benefit from the company's collaboration initiatives to become one of the most promising cannabis company.
Tilray (TLRY) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
We expect investors to focus on Tilray's (TLRY) pipeline updates when it reports third-quarter results.
AVEO Pharmaceuticals (AVEO) Q3 Earnings & Revenues Top Mark
by Zacks Equity Research
AVEO Pharmaceuticals' (AVEO) loss is narrower than estimated in the third quarter. Also, the company???s revenues beat estimates.